Skip to main content
M

Mabpharm Limited — Investor Relations & Filings

Ticker · 2181 HKEX Manufacturing
Open in API
Filings indexed 221 across all filing types
Latest filing 2025-04-22 AGM Information
Country HK Hong Kong
Listing HKEX 2181

About Mabpharm Limited

http://www.mabpharm.cn

Mabpharm Limited is a biopharmaceutical company focused on the research, development, production, and commercialization of monoclonal antibody (mAb) drugs and biosimilars. The core therapeutic areas include oncology (cancer) and autoimmune diseases. The company emphasizes bringing high-quality, affordable, and innovative biological drugs to the market by utilizing efficient R&D systems and low-cost manufacturing capabilities. Its robust pipeline features multiple candidates, including 9 monoclonal antibody drugs and 1 strong antibody drug.

Recent filings

Filing Released Lang Actions
NOTICE OF ANNUAL GENERAL MEETING
AGM Information Classification · 1% confidence The document is a formal notice convening the company’s Annual General Meeting, listing the date, time, venue, agenda items (receipt of financial statements, director re-elections, auditor appointment, share repurchase and issuance mandates, etc.), and proxy and voting arrangements. This clearly falls under the AGM Information category (code: AGM-R).
2025-04-22 English
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON WEDNESDAY, JUNE 18, 2025
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a FORM OF PROXY for the Annual General Meeting of Mabpharm Limited, used to solicit shareholder votes on AGM resolutions. It is part of the proxy solicitation materials sent to shareholders, rather than the report or minutes of the meeting itself. This aligns with the Proxy Solicitation & Information Statement category (PSI).
2025-04-22 English
PROPOSED RE-ELECTION OF DIRECTORS AND PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE SHARES AND PROPOSED RE-APPOINTMENT OF AUDITOR AND NOTICE OF ANNUAL GENERAL MEETING
Regulatory Filings
2025-04-22 English
2024 Annual Report
Annual Report Classification · 1% confidence The document is titled '2024 ANNUAL REPORT' for 'Mabpharm Limited'. It contains comprehensive sections including financial highlights, chairman's statement, management discussion and analysis, corporate governance, and audited financial statements (consolidated statement of profit or loss, financial position, etc.). It is clearly the full annual report for the fiscal year 2024, not an announcement or summary. FY 2024
2025-04-22 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2025
Share Issue/Capital Change Classification · 1% confidence The document is a standard HKEX Form FF301 monthly return covering movements in authorised share capital, issued shares, share options, convertibles, etc. It details changes in share capital and securities for the month ended 31 March 2025. This falls squarely under announcements of capital changes (new share issues, share option issuances, treasury movements). Therefore it is classified as a Share Issue/Capital Change filing.
2025-04-03 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024
Earnings Release Classification · 1% confidence The document is titled “ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024” and provides summarized consolidated financial highlights (revenue, profit/loss, per share figures, balance sheet items) along with a corporate profile. It is not a full statutory annual report (10-K) but rather the initial announcement of year-end financial results typical of an earnings release. Therefore, it matches the Earnings Release category. FY 2024
2025-03-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.